Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report
Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report
复制标题
DOI：
10.1002/cam4.288
复制
发表时间：
2014-10-01
期刊：
影响因子：
4
通讯作者：
Ward, William G.
中科院分区：
文献类型：
--
作者：
Corey, Robert M.;Swett, Katrina;Ward, William G.
美国外科医生学院的国家癌症数据库（NCDB）收集了美国70%癌症的人口统计和生存数据。我们想调查这个可能更具代表性的软组织肉瘤患者队列的人口统计学和生存率数据。我们选择了34个最常见的软组织肉瘤报告给NCDB，提供了每个实体包含至少50例。本报告总结了1998年至2010年向NCDB报告的63，714例患有这34种组织学不同软组织肉瘤的患者的人口统计学和生存率数据。这些肉瘤的总体生存率接近许多先前报告的下限，这是因为纳入标准具有包容性和最小偏倚。总体预后最好的是皮肤纤维肉瘤NOS（未另行说明）。（5年生存率92%）。预后最差的是去分化软骨肉瘤（5年生存率19%）。新的观察结果包括双相滑膜肉瘤的5年生存率（65%）高于梭形细胞滑膜肉瘤（56%，P < 0.031）和滑膜肉瘤NOS（52%，P < 0.001）。本文提供了所有34例软组织肉瘤的人口统计学和2年及5年生存率数据。软组织肉瘤的人口统计学和生存数据的范围是前所未有的。由于大量的病例和NCDB的包容性，不限于某些阶段，类别或治疗，它较少受到选择偏倚的影响。因此，考虑到目前在NCDB贡献部位对肉瘤的管理，这些数据被认为更能反映真实的总体预后。
The National Cancer Data Base (NCDB) of the American College of Surgeons gather demographic and survival data on similar to 70% of cancers in the USA. We wanted to investigate the demographic and survivorship data on this potentially more representative cohort of patients with soft tissue sarcomas. We selected 34 of the most commonly encountered soft tissue sarcomas reported to the NCDB, provided that each entity contained a minimum of 50 cases. This report summarizes the demographic and survivorship data on 63,714 patients with these 34 histologically distinct soft tissue sarcomas reported to the NCDB from 1998 to 2010. The overall survivorships of these sarcomas were near the lower limits of many prior reports due to the all-inclusive, minimally biased inclusion criteria. The overall best prognosis was Dermatofibrosarcoma NOS (not otherwise specified). (5-year survivorship 92%). The worst prognosis was Dedifferentiated Chondrosarcoma (5-year survivorship 19%). New observations included Biphasic Synovial Sarcoma demonstrating a better 5-year survivorship (65%) compared to spindle-cell synovial sarcoma (56%, P < 0.031) and Synovial Sarcoma, NOS (52%, P < 0.001). The demographic and 2-and 5-year survivorship data for all 34 soft tissue sarcomas are presented herein. This extent of demographic and survival data in soft tissue sarcomas is unprecedented. Because of the large number of cases and the inclusive nature of the NCDB, without restriction to certain stages, categories, or treatments, it is less subject to selection bias. Therefore, these data are thought to be more reflective of the true overall prognosis given the current management of sarcoma across the NCDB contributing sites.